News and Trends 29 Aug 2017 Gilead’s €10Bn Buyout of Kite Pharma Shakes European CAR-T Stocks European CAR-T stocks have jumped following Gilead’s announcement that it will acquire Kite Pharma, Novartis’ main competitor to launch the first therapy. Yesterday, Gilead bought a $11.9Bn (€9.9Bn) ticket to enter the final leg of the race to launch the first CAR-T therapy, a technology that is expected to change how cancer is treated. Despite the technology’s […] August 29, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 28 Aug 2017 Austrian Biotech Gets €25M of EU Funding to Fight Rare Childhood Cancer Apeiron Biologics has been granted financing of €25M from the European Investment Bank (EIB) to support the development of new treatments for cancer. Apeiron Biologics is a biotech based in Vienna focused on developing immuno-oncology treatments designed to make the immune system attack cancer cells. The EIB has decided to support the company’s research of a […] August 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 28 Aug 2017 Samsung Bioepis Gets European Approval for Biosimilar of Best-Selling Antibody Samsung Bioepis has announced the European Commission approved Imraldi, a biosimilar of AbbVie’s Humira (adalimumab), which has topped revenue charts for years. Samsung Bioepis’ Imraldi has now marketing authorization in the EU as a biosimilar of Humira (adalimumab) for the treatment of over 10 inflammatory indications, including rheumatoid arthritis, psoriasis, Crohn’s disease and ulcerative colitis. This makes […] August 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 24 Aug 2017 Merck Ventures Joins Series A of Brisith Biotech Using Macrophages to Fight Cancer Merck Ventures has joined the team of investors behind Macrophage Pharma, a biotech in Windsor, UK, using macrophages against cancer. Macrophage Pharma is a young biotech working on a new approach to boost the immune system’s ability to attack tumor cells. Its technology attracted £9M (€9.8M) in Series A earlier this year from the CRT Pioneer […] August 24, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 23 Aug 2017 Boehringer Ingelheim Enters the Clinic with Two New Diabetes Drugs Boehringer Ingelheim starts two new Phase I trials with drugs intended to treat type 2 diabetes and obesity discovered through a partnership with Danish biotech Zealand. The new Phase I trials initiated by Boehringer Ingelheim will be conducted in Germany, with results expected at the end of 2018. The drugs evaluated will be a long-acting […] August 23, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 23 Aug 2017 Dutch Biotech could treat Dyslipidemia with Belgian Nanobody Argenx’ partner Staten Biotechnology has published results that present a drug licensed from the Belgian biotech as a promising approach to control blood lipid levels. Staten Biotechnology is a young biotech in Breda, the Netherlands, focusing on treating dyslipidemia and reduce cardiovascular mortality and backed by BioGeneration Ventures and Forbion Capital Partners as investors. Back […] August 23, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 23 Aug 2017 Update: British Biotech’s Gene Therapy for Rare ‘Bubble Baby’ Disease set on UK Fast-Track UPDATE (23/08/2017): The UK has also prioritized OTL-101 for review as a ‘Promising Innovative Medicine.’ This is the first step on the path to the Early Access to Medicine Scheme to bring it to market faster. Original Publication 24/07/2017 Orchard Therapeutics has received rare pediatric disease designation for OTL-101, a gene therapy for the treatment of […] August 23, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 22 Aug 2017 Eli Lilly Partners with German Biotech Against Autoimmune Disease Topas Therapeutics has signed a multi-year agreement with Eli Lilly to develop drug candidates for antigen-specific immunotherapy. The young Topas Therapeutics, a spin off from Evotec launched just last year, has managed to sign a research collaboration deal with big pharma Eli Lilly. The partners will work together on selecting external antigens that induce inflammation and autoimmune disease […] August 22, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Aug 2017 First-in-Human Trial will test a New Cancer Therapy from Switzerland Cellestia Biotech will start human trials with CB-103, an anticancer drug targeting the Notch signaling pathway, known for its ubiquity in cancer. Cellestia Biotech, based in Basel, has announced it received full approval to start clinical trials in Spain with CB-103, a new class of drug that targets an ubiquitous cancer mechanism. The drug is a […] August 21, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Aug 2017 German Biotech Starts Trials with a Personalized Cell Therapy for Multiple Cancers Immatics will start a first clinical trial to test IMA101, a personalized cell therapy with the potential to treat multiple types of solid tumors. Based in Tübingen, Germany, Immatics has announced today the start of its first clinical trial testing its cell therapy technology aimed at providing personalized treatments for multiple types of solid tumors. The […] August 21, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Aug 2017 AstraZeneca Teams Up with German Biotech to Develop mRNA Therapy AstraZeneca and its R&D arm MedImmune have partnered with Munich-based Ethris to use its mRNA technology to develop treatments for respiratory disease. Ethris, located in the Munich biotech hub of Martinsried, has attracted the attention of AstraZeneca with its mRNA platform despite still being in an early development stage. The big pharma will pay Ethris €25M […] August 21, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 18 Aug 2017 Novo Nordisk’s New Type 2 Diabetes Drug Outperforms Eli Lilly’s Novo Nordisk has reported Phase III data that reveal its candidate semaglutide improved glucose control and weight loss in type 2 diabetes when compared with Eli Lilly’s dulaglutide. The results of the SUSTAIN 7 trial comparing the efficacy of Novo Nordisk’s semaglutide with Eli Lilly’s Trulicity (dulaglutide), already in the market, have revealed that Novo’s […] August 18, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email